

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association between fasting blood glucose levels and stroke events: a large-scale community-based cohort study from China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050234
Article Type:	Original research
Date Submitted by the Author:	15-Feb-2021
Complete List of Authors:	Zhang, Ya; Soochow University Medical College, School of Public Health Gu, Shujun; Changshu Center for Disease Control and Prevention Wang, Cuicui; Soochow University Medical College Liu, Dong; Soochow University Medical College Zhang, Qiuyi; Changshu Center for Disease Control and Prevention Yang, Man; Changshu Center for Disease Control and Prevention Zhou, Zhengyuan; Changshu Center for Disease Control and Prevention Zuo, Hui; Soochow University Medical College
Keywords:	Stroke < NEUROLOGY, DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Association between fasting blood glucose levels and stroke**
4 **events: a large-scale community-based cohort study from China**
5
6
7
8
9

10 Ya Zhang ^{1,2,#}, Shujun Gu ^{3,#}, Cuicui Wang ^{1,2}, Dong Liu ^{1,2}, Qiuyi Zhang ³, Man
11 Yang ³, Zhengyuan Zhou ³, Hui Zuo ^{1,2,*}
12
13
14

15
16 ^a School of Public Health, Medical College of Soochow University, Suzhou 215123,
17 China
18

19
20 ^b Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric
21 Diseases, Medical College of Soochow University, Suzhou 215123, China
22

23
24 ^c Changshu Center for Disease Control and Prevention, Suzhou 215123, China
25

26 *# Ya Zhang and Shujun Gu contributed equally to this work.*
27
28

29
30 *** Corresponding Author:** Hui Zuo, School of Public Health, Medical College of
31 Soochow University, Suzhou, China, 199 Ren'ai Rd., Suzhou 215123, China. Email:
32 zuohui@suda.edu.cn.
33
34
35
36

37 **Running title:** Fasting blood glucose levels and stroke risk
38
39

40 **Word count:** 2721
41

42 **Number of Tables:** 4
43

44 **Number of Figures:** 1
45
46

47 **Disclosure of conflict of interest:** None
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Diabetes mellitus has been associated with stroke. However, the association between fasting blood glucose (FBG) and stroke risk in general population remains still not clear. The purpose of our study was to examine the FBG levels on subsequent stroke risk in a community-based cohort in China.

Design: Prospective cohort study, employing Cox proportional hazard model to analyze the association of FBG levels with stroke risk.

Setting: A community-based cohort study included adults participating a baseline survey conducted in 2013 in Changshu, eastern China.

Participants: 16,113 participants were recruited with a multi-stage sampling method, excluding participants with severe disability, severe cancer, severe psychiatric disturbance, or previous stroke before enrolment.

Primary and secondary outcome measures: FBG levels and stroke events.

Results: During a median follow-up of 5.5 years, 417 incident cases of stroke were identified. The adjusted HR for total and ischemic stroke for participants in the fourth quartile of FBG compared with the first quartile was 1.45 (95% CI: 1.06, 1.97) and 1.56 (95% CI: 1.09, 2.23), respectively. The risk associations were consistent if classifications of FBG levels following the American Diabetes Association and WHO criteria were used. In stratified analyses, risk associations existed in women (HR: 1.93, 95% CI: 1.22, 3.05) and among postmenopausal women (HR: 1.68, 95% CI: 1.06-2.68) for the fourth quartile vs. the first. More importantly, the meta-analysis observed a positive association between FBG levels and stroke risk [pooled HR: 1.70, 95% CI: 1.28, 2.24; n=7)].

1
2
3
4
5 **Conclusions:** Higher FBG level was independently associated with an increased risk
6 of stroke in Chinese adults, especially significant in women.
7
8
9

10 **Keywords:** Stroke, Glucose, Risk, Cohort studies
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- Large sample size, measurement of plasma FBG, and complete follow-up.
- This study provides the first meta-analysis studying the association between FBG levels and stroke risk in a general population.
- No data available on HbA1c measurements in this study.

For peer review only

Introduction

Stroke is one of the most important causes of human diseases and death¹. According to the statistics of global disease burden in 2013, about 25.7 million stroke patients and 6.5 million stroke deaths worldwide². There are 113 million disability-adjusted life years caused by stroke each year³. It poses a heavy psychological and economic burden to patients' families and society. Therefore, the primary prevention of stroke has now become a top priority for global public health. In China, it has become the leading cause of death⁴ and one of the important reasons for disability in adults⁵.

Studies have shown that diabetes mellitus can increase the risk of stroke^{6,7}. A cohort study involving 510,000 people observed that diabetes significantly increased the risk of ischemic stroke and hematencephalon⁷. A meta-analysis of 58,160 patients with type 2 diabetes in China revealed that intensive blood glucose treatment could not reduce the incidence of stroke compared with conventional treatment⁸. A prospective study showed that insulin resistance or diagnosed diabetes can predict the first stroke⁹. However, these studies focus on diabetes status instead of continuous glucose levels as the study exposure, which limits the generalizability of the research findings. Since fasting blood glucose (FBG) is the least interfered by diet¹⁰, the FBG levels are considered as a more reliable tool to measure blood glucose levels than random blood glucose levels¹¹. FBG levels have a stronger predictive function for functional prognosis than random blood glucose levels. Although diabetes is closely related to cardiovascular disease (CVD), there is still insufficient data to support the evidence-based medicine proposal of strictly controlling FBG to prevent stroke.

Therefore, a further study focusing on the relationship between FBG levels and stroke is crucial, which can help us know whether people who are suffering from diabetes, impaired fasting glucose (IFG), insulin resistance, or other people with higher FBG levels should take prevention strategies against stroke. In this study, a community

1
2
3
4 population from China was followed up for 5.5 years to study the relationship
5
6 between FBG levels and the incidence of stroke, aiming at providing suggestions and
7
8 a basis for primary prevention of stroke among people with different FBG levels.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods

Study population

The baseline survey of the current cohort study was conducted in 2013. The source population was 20,343 participants aged 35-74 years in rural communities in Changshu, eastern China who participated in an earlier study on metabolic syndrome in 2008, in addition to a small proportion of new participants. A multi-stage sampling method was used to recruit participants. Individuals with severe disability, severe cancer, or a severe psychiatric disturbance were excluded. Of these, 16,457 subjects in total were included in the baseline survey. We excluded 137 patients with a previous stroke before enrolment. Participants with missing data on baseline health information (n=207) were also excluded, leaving 16,113 participants in total for final analyses.

Laboratory measurements

Blood samples were collected in the morning after overnight fasting and evaluated biochemical and clinical parameters on the same day. FBG was measured by an oxidase enzymatic method. The levels of high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglyceride (TG) were assessed enzymatically using commercial reagents with an automatic biochemistry analyzer (Hitachi Inc, Tokyo, Japan).

Follow-up and ascertainment of stroke

Follow-up began at the baseline and ended at the date of stroke diagnosis, death, or December 31, 2018, whichever came first. We classified total stroke into an ischemic stroke, and non-ischemic stroke (including hemorrhagic stroke, subarachnoid hemorrhage, and unexplained types of stroke). The primary outcome was

1
2
3
4 hospitalization or death due to stroke collected by ICD-10 codes (total stroke: I60-I61,
5 I63-I64; ischemic stroke: 63 except I63.9). If a participant had more than 1 stroke
6 event during the follow-up, only the first stroke was considered.
7
8
9

11 **Assessments of covariates**

12
13
14
15 Demographic characteristics, lifestyle factors, personal medical history [CVD,
16 hyperlipidemia, hypertension, diabetes, chronic obstructive pulmonary disease
17 (COPD), nephropathy, and cancer], and family history data for all participants were
18 obtained using standard questionnaires administered by trained staff. After the
19 subjects rested for 5 minutes, the trained observers used an electronic
20 sphygmomanometer (Omron Hp1300, OMRON Corporation, China) to measure the
21 blood pressure in the sitting position three times every 30 seconds. The criteria for
22 judging hypertension are a continuous measurement of systolic blood pressure \geq
23 140mmHg or diastolic blood pressure \geq 90mmHg, diagnosis of hypertension, or
24 antihypertensive medication. The body mass index (BMI) was calculated as weight in
25 kilograms divided by the square of height in meters, among weight and height were
26 measured by standard methods.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

42 **Meta-analysis**

46 We conducted a meta-analysis combining the current study findings with previous
47 observations on FBG and stroke risk. We searched the Medline and PubMed
48 databases for related research articles published between January 01, 2000-September
49 10, 2020 using the keywords “stroke”, “cardiovascular disease” and “fasting blood
50 glucose”, “blood glucose”, “fasting glucose”, “fasting plasma glucose”, “glucose”, in
51 addition to “prospective study”, “cohort study”, or “follow-up”. The study subjects
52 were restricted to apparently healthy adults in the community. Two authors extracted
53 the data independently, and if they had disagreements, discussed it with the third
54
55
56
57
58
59
60

1
2
3
4 author. Finally, seven studies were included¹²⁻¹⁷. We extracted information about
5 authors, sample size, the country where the study was implemented, time of
6 follow-up, adjusted covariates, outcome (stroke events), and the effect size [hazard
7 ratio (HR)]. We used a random-effect model to calculate the pooled risk estimation
8 based on the assumption of study heterogeneity. The Begg and Egger tests were
9 performed to detect potential publication bias.¹⁸
10
11
12
13
14
15
16

17 **Statistical analysis**

18
19
20
21 Baseline demographic characteristics for continuous variables were expressed as
22 median (interquartile ranges), and categorical variables were presented as
23 percentages. Log-transformation was used to all laboratory measures to normalize
24 distributions.
25
26
27
28
29
30

31 Cox proportional hazard analyses were conducted to evaluate FBG levels and risk of
32 stroke and results presented as HR and 95% confidence intervals (CI). FBG levels
33 were included in the models as a categorical measure (quartiles and three categories
34 by clinical criteria). Multivariable models included conventional risk factors at
35 baseline: age (continuous), sex, BMI (continuous), current smoking (yes/no), family
36 history of stroke (yes/no), hypertension (yes/no), HDL-C (mmol/L), TC (mmol/L),
37 TG (mmol/L) and use of statins. IFG is defined as an FBG of 6.1-6.9 mmol/L by
38 WHO¹⁹ and an FBG of 5.6-6.9 mmol/L by the American Diabetes Association
39 (ADA)²⁰. We also used clinical classification (normal FBG, IFG, hyperglycemia) to
40 classify FBG levels. In addition, we conducted stratified analyses by sex to check
41 potential effect modification. Sensitivity analyses were conducted to determine the
42 robustness of the primary analysis results. We limited the risk-association analyses to
43 participants who didn't report their own medical history, including hypertension,
44 hyperlipidemia, cancer, nephropathy, CVD, or COPD at baseline.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analyses were conducted with R (version 4.0.2, www.r-project.org). All

1
2
3
4 tests were 2-sided, and a P value less than 0.05 was considered statistically
5
6 significant.
7
8

9
10 **Patient and public involvement**
11

12
13 Patients and the public were not involved this research.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Results

Characteristics of the study population

After a median follow-up of 5.5 years (range: 0.1-5.7 years), a total of 417 (192 men and 225 women) stroke events were identified, of which 323 (77.5%) were ischemic stroke. Table 1 shows the baseline characteristics of participants across the quartiles of FBG. Compared with the participants in the study with lower FBG, those with higher FBG levels were more likely to suffer from obesity, hypertension, and hyperlipidemia, had higher levels of TC and TG in the blood, and preferred to have a family history of stroke ($P<0.001$, Table 1).

FBG levels and risk of stroke

As shown in Table 2, we observed that higher FBG levels were significantly correlated with an increased risk of total and ischemic stroke in both the original models and models adjusted for age, sex, BMI, HDL-C, TC, TG, hypertension, smoking status, use of statins and family history of stroke. Compared to the lowest FBG quartile, the multivariable-adjusted HRs for the highest quartile were 1.45 (95% CI: 1.06-1.97, $P=0.021$) for total and 1.56 (95%CI: 1.09-2.23, $P=0.016$) for ischemic stroke. A positive association between FBG levels and non-ischemic stroke was observed in the crude model, but the risk association was rendered statistically nonsignificant in adjusted models. Further, we examined the association between clinical classifications of FBG levels and stroke risk, and the results are presented in Table 3. The multivariable-adjusted HR for total stroke was 1.68 (95%CI: 1.26-2.25, $P=0.001$) and 1.60 (95% CI: 1.21-2.12, $P=0.002$) for participants with hyperglycemia compared with those with normal blood glucose, following the ADA and WHO recommendations, respectively.

1
2
3
4 Results of sex-stratified analyses are shown in Table 4. We observed a positive
5 correlation between the FBG levels and total stroke in men in the unadjusted model,
6 but not in adjusted models. In original models, higher levels of FBG were
7 significantly associated with an increased risk of total stroke in women. After
8 adjustment covariate for age, BMI, and other variates, the risk association remained
9 significant (HR: 1.93, 95%CI: 1.22-3.05, P=0.004) for the fourth level in female
10 groups. Similar risk estimates were found in postmenopausal or oophorectomy
11 women. But no significant association with stroke was observed for FBG levels in
12 premenopausal women (supplemental appendix S1).
13
14
15
16
17
18
19
20
21
22

23 In sensitivity analyses, the study population was restricted to 15,404 subjects without
24 a self-reported history of hyperlipidemia, CVD, cancer, nephropathy, and COPD
25 yielded essentially no change in risk of total stroke (HR: 1.38, 95% CI: 1.01, 1.92)
26 and ischemic stroke (HR: 1.55, 95% CI: 1.06, 2.26). Additional eliminated for
27 participants with hypertension, the association in women was slightly raised for total
28 stroke (HR: 2.50, 95% CI: 1.11, 5.60) and ischemic stroke (HR: 2.59, 95% CI: 1.03,
29 6.51) (data not shown).
30
31
32
33
34
35
36
37
38

39 **Meta-analysis**

40
41
42 Figure 1 shows the results of meta-analysis including six previously published
43 prospective studies together with our current study. In a word, higher FBG levels
44 were associated with an increased risk of stroke (pooled HR: 1.70, 95% CI: 1.27-2.29).
45 The Begg and Egger tests didn't suggest existence of potential publication bias (P>0.1
46 for both tests).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Principal findings

In our prospective community-based cohort, higher FBG levels were associated with an increased risk of total and ischemic stroke. The risk-association was prominent in women. After excluding the baseline of hypertension, hyperlipidemia, CVD, cancer, nephropathy, and COPD, these associations were still persisted in analyses of women. Our findings extend the previous knowledge on diabetes and stroke risk, suggesting an important role of routine glucose measurement in stroke prevention.

Associations of FBG with stroke risk

When analyzing stroke subtypes, there is no evidence that FBG is associated with non-ischemic stroke, but the association with ischemic stroke persists. This is consistent with the results of a prospective cohort study among Korean men¹⁴. It suggests that the correlation between FBG and stroke is mainly contributed by an ischemic stroke. A large-scale prospective study in China (including 96,110 participants) indicated that both hyperglycemia and hypoglycemia are associated with an increased risk of incident intracerebral hemorrhage, after adjustment for potential confounders²¹.

Results based on the ADA and WHO criteria demonstrated that FBG levels of ≥ 7.0 mmol/L were a significant risk factor for stroke [HR (95% CI): 1.68 (1.26, 2.55) and 1.60 (1.21, 2.12) following the ADA and WHO criteria, respectively], whereas IFG was not. A large number of studies showed that people with diabetes are at increased risk of ischemic stroke^{22, 23}. A meta-analysis including 698,782 participants reported that the risk of ischemic stroke in diabetic patients was 2.27 times higher than normal people²². A cohort study in Swedish also showed that poor blood glucose control in

1
2
3
4 patients with type 2 diabetes was associated with an increased risk of stroke and
5 death²³. Although diabetes is associated with stroke, the influence of prediabetes on
6 future stroke risk has not been clear yet. In a meta-analysis including 15 cohort
7 studies, more than half of the studies showed that after adjusting for cardiovascular
8 risk factors, there was no significant association between pre-diabetes and stroke²⁴. A
9 cohort study investigated the sex-specific associations of pre-diabetes with major
10 clinical outcomes reached the same conclusion²⁵. Our findings on IFG and stroke also
11 resemble the previously reported results.
12
13
14
15
16
17
18
19
20

21 Stratified analysis showed that the correlation between FBG levels and stroke risk
22 only existed in women. According to the re-stratification of menopause, only
23 postmenopausal women with the highest FBG level had a higher risk of stroke [HR
24 (95% CI): 1.68 (1.06, 2.68)], no associations were found in premenopausal women. It
25 probably due to the low number of stroke events in premenopausal women. Few
26 published studies reported sex-stratified results. A sex-specific cohort study in the
27 Middle East showed that only men with higher FBG levels showed an increased risk
28 of stroke [HR: 2.15(1.26, 4.67) in FBG level of 6.1-6.9 mmol/L, HR: 2.38 (1.08, 5.25)
29 in FBG level of >7.0 mmol/L]²⁶. Korean Heart Study showed that IFG was associated
30 with an increased risk of ischemic stroke in men but not in women²⁷. We suspect that
31 the disparities in sex between studies could be due to different definitions of outcome
32 (all stroke vs. ischemic stroke) and the variety in covariate adjustments. A
33 meta-analysis including 64 cohort studies provides the clearest evidence yet for the
34 sex difference of diabetes and stroke risk. The excess risk of diabetes-related stroke in
35 women is significantly higher than that in men and independent of sex-difference in
36 other cardiovascular risk factors²⁸. Our results support the findings of this
37 meta-analysis, indicating that the association between FBG levels and stroke cases in
38 women, and the mechanism may be related to the protective effect of estrogen.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Possible mechanisms**

59
60

1
2
3
4 Accumulating evidence suggests that FBG levels can be used to predict the risk of
5 CVD^{15, 22, 29}. As an adverse consequence of CVD, stroke is closely related to FBG
6 levels^{30, 31}. Its mechanism may be related to the dysfunction of cerebral
7 microvasculature caused by hyperglycemia, insulin resistance, obesity, and
8 hypertension³². The microvasculature is involved in the regulation of many brain
9 processes. Once damaged, it's easy to cause cerebrovascular accidents³³. The
10 dysfunction is also obvious in the prediabetes population, which may suggest that IFG
11 is the risk factor for stroke³⁴. Besides, diabetic retinopathy was proved to be a sign of
12 lacunar ischemic stroke, which had the same effects as cerebral microvascular
13 dysfunction³⁵.

14
15
16
17
18
19
20
21
22
23
24
25 Compared with men, women with diabetes are at higher risk of stroke²⁸. Previously, it
26 was thought that the sex specificity of the severity of diabetes-related cardiovascular
27 diseases was caused by the differences between men and women in treatment and
28 chronic disease management. However, as the gradual equality of men and women,
29 the risk of serious cardiovascular disease in postmenopausal women is still higher²⁸.
30 Sex hormones may explain the sex differences observed in human epidemiological
31 studies³⁶⁻³⁸, indicating the estrogen protection in women, preventing the progression
32 of non-diabetic cardiovascular diseases at least before menopause. Animal
33 experiments show that the decrease of estrogen levels in ovariectomized mice can
34 lead to impaired glycemia, reduced glucose tolerance, hyperinsulinemia, and impaired
35 insulin secretion, and then develop into hyperglycemia and atherosclerosis³⁹.
36 However, diabetes seemingly attenuates the protective effect of estrogen on women in
37 the development of CVD⁴⁰.

38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 **Strengths and Limitations**

53
54
55
56 The main strengths of this study include the large sample size, measurement of
57 plasma FBG, and the complete follow-up. We followed up the cases by recording
58 linkages with hospital discharge diagnoses and the Cause of Death Registry. We used
59
60

1
2
3
4 both quartiles and clinical classifications (normal FBG, IFG, hyperglycemia) to
5 classify FBG levels, and obtained similar results. We considered different stroke
6 subtypes as the study outcome. To our knowledge, this study provides the first
7 meta-analysis investigating the association between FBG levels and stroke risk in the
8 general population, therefore results are likely generalizable to all races.
9
10
11
12
13
14

15 Our study has several limitations. First, we do not have HbA_{1c} measurements in this
16 study. Among indicators to assess glucose variability, HbA_{1c} is the gold standard for
17 clinical evaluation of long-term blood glucose control⁹, while FBG may overlook the
18 potential effects of postprandial blood glucose levels and other meaningful factors⁴¹.
19
20
21
22
23 Second, the levels of estradiol and testosterone in the study subjects were not
24 measured, although we speculated that the sex difference was probably due to the
25 protective effect of sex hormone. Third, due to a low number of stroke cases, the real
26 risk association of the premenopausal population may be biased.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions

Our study indicates that higher FBG levels are associated with an increased stroke in the general population, and meta-analysis corroborated this finding. Further, we observed that the association was more prominent in women than in men. We also observed strong risk associations among postmenopausal or oophorectomy women. FBG levels as a routine and low-cost measurement could be used to identify individuals with higher stroke risk in the future.

Contributors

Conceptualization, YZ and HZ; methodology, YZ; software, YZ; validation, YZ; formal analysis, YZ; resources, SG, QZ, MY and ZZ; data curation, YZ; visualization, YZ; investigation, YZ, CW and DL; writing—original draft preparation, YZ; writing—review and editing, YZ and HZ; supervision, HZ; project administration, HZ; funding acquisition, HZ. All authors have agreed on the journal to which the article has been submitted and agreed to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [Nos. 81973122].

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

The study protocol conforms to the ethical guidelines of the Declaration of Helsinki. The baseline survey and record linkages with study outcomes were approved by the

1
2
3
4 Ethics Committee of Fuwai Cardiovascular Hospital, Beijing, China (No. 2012-399).
5
6 After a detailed explanation of our study, we obtained a written informed consent
7
8 form from each participant.
9
10

11 **Provenance and peer review**

12
13
14
15

16 Not commissioned; externally peer reviewed.
17
18
19

20 **Data availability statement**

21
22
23
24

25 The datasets generated and/or analyzed during the current study are not publicly
26 available due to the restrictions of containing information that could compromise the
27
28 privacy of research participants.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Feigin V, Roth G, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet Neurology*. 2016;15(9):913-24.
DOI: [10.1016/S1474-4422\(16\)30073-4](https://doi.org/10.1016/S1474-4422(16)30073-4)
2. Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. *Circulation Research*. 2017;120(3):439-48. DOI: [10.1161/CIRCRESAHA.116.308413](https://doi.org/10.1161/CIRCRESAHA.116.308413)
3. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. *Neuroepidemiology*. 2015;45(3):161-76. DOI: [10.1159/000441085](https://doi.org/10.1159/000441085)
4. Wang W, Jiang B, Sun H, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. *Circulation*. 2017;135(8):759-71. DOI: [10.1161/CIRCULATIONAHA.116.025250](https://doi.org/10.1161/CIRCULATIONAHA.116.025250)
5. Liu L, Wong L, Wang D, et al. Current status of endovascular procedures in management of ischemic stroke in China. *CNS Neurosci Ther*. 2014;20(6):483-4. DOI: [10.1111/cns.12281](https://doi.org/10.1111/cns.12281)
6. Banerjee C, Moon Y, Paik M, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. *Stroke*. 2012;43(5):1212-7. DOI: [10.1161/STROKEAHA.111.641381](https://doi.org/10.1161/STROKEAHA.111.641381)
7. Bragg F, Li L, Yang L, et al. Risks and Population Burden of Cardiovascular Diseases Associated with Diabetes in China: A Prospective Study of 0.5 Million Adults. *PLoS Medicine*. 2016;13(7): e1002026. DOI: [10.1371/journal.pmed.1002026](https://doi.org/10.1371/journal.pmed.1002026)
8. Fang H, Zhou Y, Tian Y, et al. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials. *Int J Cardiol*. 2016; 218:50-8. DOI: [10.1016/j.ijcard.2016.04.163](https://doi.org/10.1016/j.ijcard.2016.04.163)
9. Jia Z, Wu S, Zhou Y, et al. Metabolic syndrome and its components as predictors of stroke in middle-aged and elderly Chinese people. *Neurol Res*. 2011;33(5):453-9. DOI: [10.1179/016164111X13007856083882](https://doi.org/10.1179/016164111X13007856083882)

- 1
2
3
4 10. Moebus S, Göres L, Lössch C, et al. Impact of time since last caloric intake on
5 blood glucose levels. *Eur J Epidemiol.* 2011;26(9):719-28.
6
7 DOI: [10.1007/s10654-011-9608-z](https://doi.org/10.1007/s10654-011-9608-z)
8
9 11. Morris HJDC. Standards of Medical Care in Diabetes. *Diabetes Care.*
10 2014;36(Suppl 1):S11-S66.
11
12 12. Nielson C, Fleming RMJA. Blood glucose and cerebrovascular disease in
13 nondiabetic patients. *Angiology.* 2007;58(5):625-9.
14
15 DOI: [10.1177/0003319707303695](https://doi.org/10.1177/0003319707303695)
16
17 13. Boden-Albala B, Cammack S, et al. Diabetes, fasting glucose levels, and risk of
18 ischemic stroke and vascular events: findings from the Northern Manhattan Study
19 (NOMAS). *Circulation.* 2008;31(6):1132. DOI: [10.2337/dc07-0797](https://doi.org/10.2337/dc07-0797)
20
21 14. Sung J, Song YM, Ebrahim S, et al. Fasting blood glucose and the risk of stroke
22 and myocardial infarction. *Circulation.* 2009;119(6):812-9.
23
24 DOI: [10.1161/CIRCULATIONAHA.108.776989](https://doi.org/10.1161/CIRCULATIONAHA.108.776989)
25
26 15. Liu F, Yang X, Li J, et al. Association of fasting glucose levels with incident
27 atherosclerotic cardiovascular disease: An 8-year follow-up study in a Chinese
28 population. *J Diabetes.* 2017;9(1):14-23. DOI: [10.1111/1753-0407.12380](https://doi.org/10.1111/1753-0407.12380)
29
30 16. Lee G, Kim SM, Choi S, et al. The effect of change in fasting glucose on the risk
31 of myocardial infarction, stroke, and all-cause mortality: a nationwide cohort study.
32 *Cardiovasc Diabetol.* 2018;17(1):51. DOI: [10.1186/s12933-018-0694-z](https://doi.org/10.1186/s12933-018-0694-z)
33
34 17. Peng X, Ge J, Wang C, et al. Longitudinal Average Glucose Levels and Variance
35 and Risk of Stroke: A Chinese Cohort Study. *Int J Hypertens.* 2020; 2020:8953058.
36
37 DOI: [10.1155/2020/8953058](https://doi.org/10.1155/2020/8953058)
38
39 18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for
40 publication bias. *Biometrics.* 1994;50(4):1088-101.
41
42 19. WHO Guidelines Approved by the Guidelines Review Committee. Use of
43 Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated
44 Report of a WHO Consultation. Geneva: World Health Organization Copyright ©
45 World Health Organization, 2011.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 20. Johnson EL, Feldman H, Butts A, et al. Standards of Medical Care in
5 Diabetes—2020 Abridged for Primary Care Providers. *Clin Diabetes*. 2019;43(Suppl.
6 1):S1-S212. DOI: [10.2337/cd20-as01](https://doi.org/10.2337/cd20-as01)
7
8
9 21. Jin C, Li G, Rexrode KM, et al. Prospective Study of Fasting Blood Glucose and
10 Intracerebral Hemorrhagic Risk. *Stroke*. 2018;49(1):27-33.
11
12 DOI: [10.1161/STROKEAHA.117.019189](https://doi.org/10.1161/STROKEAHA.117.019189)
13
14 22. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose
15 concentration, and risk of vascular disease: a collaborative meta-analysis of 102
16 prospective studies. *Lancet*. 2010;375(9733):2215-22.
17
18 DOI: [10.1016/S0140-6736\(10\)60484-9](https://doi.org/10.1016/S0140-6736(10)60484-9)
19
20 23. Zabala A, Darsalia V, Holzmann MJ, et al. Risk of first stroke in people with type
21 2 diabetes and its relation to glycaemic control: A nationwide observational study.
22 *Diabetes, Obes and Metab*. 2019;22(2):182-90. DOI: [10.1111/dom.13885](https://doi.org/10.1111/dom.13885)
23
24 24. Lee M, Saver JL, Hong KS, et al. Effect of pre-diabetes on future risk of stroke:
25 meta-analysis. *BMJ*. 2012; 344: e3564. DOI: [10.1136/bmj.e3564](https://doi.org/10.1136/bmj.e3564)
26
27 25. Shang Y, Fratiglioni L, Marseglia A, et al. Association of diabetes with stroke
28 and post-stroke dementia: A population-based cohort study. *Alzheimers Dement*.
29 2020;16(7):1003-12. DOI: [10.1002/alz.12101](https://doi.org/10.1002/alz.12101)
30
31 26. Parizadeh D, Rahimian N, Akbarpour S, et al. Sex-specific clinical outcomes of
32 impaired glucose status: A long follow-up from the Tehran Lipid and Glucose Study.
33 *Eur J Prev Cardiol*. 2019;26(10):1080-91. DOI: [10.1177/2047487319834396](https://doi.org/10.1177/2047487319834396)
34
35 27. Kim HK, Kim CH, Kim EH, et al. Impaired fasting glucose and risk of
36 cardiovascular disease in Korean men and women: the Korean Heart Study. *Diabetes*
37 *Care*. 2013;36(2):328-35. DOI: [10.2337/dc12-0587](https://doi.org/10.2337/dc12-0587)
38
39 28. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in
40 women compared with men: a systematic review and meta-analysis of 64 cohorts,
41 including 775,385 individuals and 12,539 strokes. *Lancet*. 2014;383(9933):1973-80.
42
43 DOI: [10.1016/S0140-6736\(14\)60040-4](https://doi.org/10.1016/S0140-6736(14)60040-4)
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 29. Bragg F, Li L, Smith M, et al. Associations of blood glucose and prevalent
5 diabetes with risk of cardiovascular disease in 500 000 adult Chinese: the China
6 Kadoorie Biobank. *Diabetic Med.* 2014;31(5):540-51. DOI: [10.1111/dme.12392](https://doi.org/10.1111/dme.12392)
7
8
9
10 30. Luitse MJ, Biessels GJ, Rutten GE, et al. Diabetes, hyperglycaemia, and acute
11 ischaemic stroke. *The Lancet Neurology.* 2012;11(3):261-71.
12
13 DOI: [10.1016/S1474-4422\(12\)70005-4](https://doi.org/10.1016/S1474-4422(12)70005-4)
14
15 31. Liu J, Rutten-Jacobs L, Liu M, et al. Causal Impact of Type 2 Diabetes Mellitus
16 on Cerebral Small Vessel Disease: A Mendelian Randomization Analysis. *Stroke.*
17 2018;49(6):1325-31. DOI: [10.1161/STROKEAHA.117.020536](https://doi.org/10.1161/STROKEAHA.117.020536)
18
19 32. Sloten TTV, Sedaghat S, Carnethon MR, et al. Cerebral microvascular
20 complications of type 2 diabetes: stroke, cognitive dysfunction, and depression.
21 *Lancet Diabetes Endocrinol.* 2020;8(4):325-336.
22
23 DOI: [10.1016/S2213-8587\(19\)30405-X](https://doi.org/10.1016/S2213-8587(19)30405-X)
24
25 33. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and
26 clinical implications. *The Lancet Neurology.* 2019;18(7):684-96.
27
28 DOI: [10.1016/S1474-4422\(19\)30079-1](https://doi.org/10.1016/S1474-4422(19)30079-1)
29
30 34. Stehouwer CDA. Microvascular dysfunction and hyperglycemia: a vicious cycle
31 with widespread consequences. *Diabetes.* 2018;67(9):1729-41.
32
33 DOI: [10.2337/dbi17-0044](https://doi.org/10.2337/dbi17-0044)
34
35 35. Hankey GJ, Anderson NE, Ting RD, et al. Rates and predictors of risk of stroke
36 and its subtypes in diabetes: a prospective observational study. *J Neurol Neurosur PS.*
37 2013;84(3):281-7. DOI: [10.1136/jnnp-2012-303365](https://doi.org/10.1136/jnnp-2012-303365)
38
39 36. Brann DW, Dhandapani K, Wakade C, et al. Neurotrophic and neuroprotective
40 actions of estrogen: basic mechanisms and clinical implications. *Steroids.*
41 2007;72(5):381-405. DOI: [10.1016/j.steroids.2007.02.003](https://doi.org/10.1016/j.steroids.2007.02.003)
42
43 37. Howard VJ, Madsen TE, Kleindorfer DO, et al. Sex and Race Differences in the
44 Association of Incident Ischemic Stroke With Risk Factors. *JAMA Neurol.*
45 2019;76(2):179-86. DOI: [10.1001/jamaneurol.2018.3862](https://doi.org/10.1001/jamaneurol.2018.3862)
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 38. Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke:
5 epidemiology, clinical presentation, medical care, and outcomes. *Lancet Neurol.*
6 2008;7(10):915-26. DOI: [10.1016/S1474-4422\(08\)70193-5](https://doi.org/10.1016/S1474-4422(08)70193-5)
7
8
9 39. Venegas-Pino DE, Wang PW, Stoute HK et al. Sex-Specific Differences in an
10 ApoE(-/-):Ins2(+)/Akita) Mouse Model of Accelerated Atherosclerosis. *Am J Pathol.*
11 2016;186(1):67-77. DOI: [10.1016/j.ajpath.2015.09.009](https://doi.org/10.1016/j.ajpath.2015.09.009)
12
13
14 40. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk,
15 Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev.*
16 2016;37(3):278-316. DOI: [10.1210/er.2015-1137](https://doi.org/10.1210/er.2015-1137)
17
18
19 41. Jia Q, Zheng H, Zhao X et al. Abnormal glucose regulation in patients with acute
20 stroke across China: prevalence and baseline patient characteristics. *Stroke.*
21 2012;43(3):650-7. DOI: [10.1161/STROKEAHA.111.633784](https://doi.org/10.1161/STROKEAHA.111.633784)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics of study population by FBG levels and stroke risk: Cohort Changshu.

Characteristic	Total	Quartile of FBG Levels (mmol/L)				P Value
	n=16,113	Q1 (< 4.87) n=4097	Q2 (4.87-5.24) n=4027	Q3 (5.24-5.77) n=3979	Q4 (> 5.77) n=4010	
Age, yrs	55.7 (46.3, 64.4)	48.6 (41.4, 59.1)	53.8 (44.8, 62.84)	57.8 (48.6, 65.9)	60.0 (51.4, 67.2)	<0.001
Men (%)	40.9	42.1	39.4	40.2	42.1	0.002
Premenopausal in women (%)	37.5	55.3	42.3	29.7	22.3	<0.001
Follow-up time, yrs	5.53 (5.49, 5.56)	5.52 (5.49, 5.54)	5.52 (5.49, 5.55)	5.53 (5.50, 5.57)	5.55 (5.50, 5.58)	<0.001
BMI (kg/m ²)	23.3 (21.2, 25.7)	22.6 (20.6, 24.9)	23.0 (21.0, 25.3)	23.6 (21.5, 25.9)	24.2 (22.0, 26.5)	<0.001
Current smoking (%)	23.6	26.9	23.5	21.9	21.9	<0.001
Family history of stroke (%)	5.8	3.8	5.4	6.5	7.6	<0.001
Hypertension (%)	22.8	13.9	18.6	24.9	34.0	<0.001
Fasting blood glucose, mmol/L	5.24 (4.87, 5.77)	4.66 (4.47, 4.77)	5.06 (4.97, 5.15)	5.47 (5.34, 5.60)	6.37 (6.01, 7.20)	<0.001
TC, mmol/L	4.70 (4.13, 5.36)	4.48 (3.95, 5.04)	4.62 (4.08, 5.23)	4.79 (4.22, 5.44)	4.99 (4.36, 5.70)	<0.001
TG, mmol/L	1.32 (0.96, 1.90)	1.20 (0.88, 1.68)	1.26 (0.93, 1.78)	1.33 (0.97, 1.91)	1.52 (1.08, 2.30)	<0.001
HDL-C, mmol/L	1.38 (1.14, 1.66)	1.36 (1.14, 1.62)	1.37 (1.14, 1.64)	1.40 (1.15, 2.68)	1.38 (1.14, 1.69)	<0.001
Use of statins (%)	0.4	0.1	0.3	0.3	0.7	<0.001

¹ BMI, body mass index; HDL-C, high density lipoprotein cholesterol; Q, quartile; TC, total cholesterol; TG, triglyceride.

² P Values were determined by Chi-square tests for categorical and Kruskal-Wallis tests for continuous variables.

Table 2. Hazard ratios (95% CI) for incident stroke by FBG quartiles

		Quartile of FBG Levels				P trend
		Q1	Q2	Q3	Q4	
		HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	
Total stroke	Cases/N	57/4097	89/4027	110/3979	161/4010	
	Model 1	1 (Ref.)	1.60 (1.15, 2.22)	2.00 (1.45, 2.75)	2.92 (2.16, 3.94)	<0.001
	Model 2	1 (Ref.)	1.21 (0.87, 1.69)	1.17 (0.85, 1.62)	1.46 (1.07, 1.98)	0.018
	Model 3	1 (Ref.)	1.20 (0.86, 1.68)	1.16 (0.84, 1.60)	1.45 (1.06, 1.97)	0.021
Ischemic stroke	Cases/N	42/4097	69/4027	83/3979	129/4010	
	Model 1	1 (Ref.)	1.68 (1.15, 2.47)	2.05 (1.41, 2.96)	3.17 (2.24, 4.49)	<0.001
	Model 2	1 (Ref.)	1.27 (0.87, 1.87)	1.19 (0.82, 1.73)	1.58 (1.11, 2.25)	0.013
	Model 3	1 (Ref.)	1.25 (0.85, 1.84)	1.17 (0.80, 1.71)	1.56 (1.09, 2.23)	0.016
Non-ischemic stroke	Cases/N	15/4097	20/4027	27/3979	32/4010	
	Model 1	1 (Ref.)	1.36 (0.70, 2.66)	1.86 (0.99, 3.50)	2.20 (1.19, 4.07)	0.006
	Model 2	1 (Ref.)	1.04 (0.53, 2.04)	1.13 (0.60, 2.14)	1.11 (0.59, 2.07)	0.713
	Model 3	1 (Ref.)	1.04 (0.53, 2.04)	1.13 (0.60, 2.13)	1.11 (0.69, 2.09)	0.844

Model 1: unadjusted model; Model 2: adjusted for age, sex and BMI; Model 3: further adjusted for HDL-C, TC, TG, hypertension, smoking status, use of statins and family history of stroke.

Table 3. Hazard ratios (95% CI) for incident stroke by clinical classifications of FBG levels

			Model 1	Model 2	Model 3
ADA definition	<5.6 mmol/L	Cases/N		220/11079	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	5.6–6.9 mmol/L	Cases/N		136/3869	
		HR (95%CI)	1.78 (1.43, 2.20)	1.16 (0.94, 1.44)	1.18 (0.95, 1.47)
	≥7.0 mmol/L	Cases/N		61/1165	
		HR (95%CI)	2.69 (2.02, 3.57)	1.72 (1.29, 2.28)	1.68 (1.26, 2.25)
P trend			<0.001	0.001	0.001
WHO definition	<6.1 mmol/L	Cases/N		301/13422	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	6.1–6.9 mmol/L	Cases/N		55/1526	
		HR (95%CI)	1.61 (1.21, 2.15)	1.08 (0.81, 1.45)	1.09 (0.82, 1.46)
	≥7.0 mmol/L	Cases/N		61/1165	
		HR (95%CI)	2.38 (1.81, 3.03)	1.64 (1.24, 2.17)	1.60 (1.21, 2.12)
P trend			<0.001	0.001	0.002

ADA: American Diabetes Association; WHO: World Health Organization.

Model 1: unadjusted model; Model 2: adjusted for age, sex and BMI; Model 3: further adjusted for HDL-C, TC, TG, hypertension, smoking status, use of statins and family history of stroke.

Table 4. Hazard ratios (95% CI) for incident stroke by sex


		Quartile of FBG Levels				P trend
		Q1	Q2	Q3	Q4	
		HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	
Men	Cases/N	33/1725	42/1586	53/1599	64/1688	
	Model 1	1 (Ref.)	1.40 (0.89, 2.20)	1.74 (1.13, 2.69)	1.99 (1.31, 3.03)	0.001
	Model 2	1 (Ref.)	1.04 (0.66, 1.64)	1.16 (0.75, 1.80)	1.11 (0.73, 1.71)	0.560
	Model 3	1 (Ref.)	1.04 (0.66, 1.65)	1.15 (0.74, 1.79)	1.06 (0.69, 1.64)	0.741
Women	Cases/N	24/2372	47/2441	57/2380	97/2322	
	Model 1	1 (Ref.)	1.91 (1.21, 3.29)	2.38 (1.48, 3.84)	4.19 (2.68, 6.55)	<0.001
	Model 2	1 (Ref.)	1.45 (0.89, 2.37)	1.25 (0.78, 2.03)	1.90 (1.21, 2.99)	0.006
	Model 3	1 (Ref.)	1.43 (0.87, 2.34)	1.26 (0.78, 2.05)	1.93 (1.22, 3.05)	0.004

Model 1: unadjusted model; Model 2: adjusted for age, sex and BMI; Model 3: further adjusted for HDL-C, TC, TG, hypertension, smoking status, use of statins and family history of stroke.

1
2
3
4 **Figure 1.** Meta-analysis of fasting blood glucose at the highest vs lowest levels and
5 the risk of developing stroke. The horizontal lines indicate the lower and upper limits
6 of the 95% CI, and the grey squares reflects the HR of each study. HR: Hazard Ratio.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32



Appendix S1. Hazard ratios (95% CI) for incident stroke by menopausal status in women

			Model 1	Model 2	Model 3
Premenopausal	Q1	Cases/N		1/906	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	Q2	Cases/N		5/896	
		HR (95%CI)	5.07 (0.59, 43.37)	2.97 (0.34, 25.86)	2.54 (0.29, 22.48)
	Q3	Cases/N		7/883	
		HR (95%CI)	7.19 (0.89, 58.44)	3.88 (0.47, 31.97)	3.86 (0.47, 31.78)
	Q4	Cases/N		8/884	
HR (95%CI)		8.18 (0.29, 22.48)	1.90 (0.22, 16.15)	1.80 (0.21, 15.30)	
P trend			0.013	0.850	0.916
Postmenopausal or oophorectomy	Q1	Cases/N		35/1489	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	Q2	Cases/N		42/1513	
		HR (95%CI)	1.18 (0.76, 1.85)	1.05 (0.67, 1.64)	1.06 (0.62, 1.79)
	Q3	Cases/N		49/1473	
		HR (95%CI)	1.42 (0.92, 2.19)	1.07 (0.69, 1.66)	1.14 (0.70, 1.87)
	Q4	Cases/N		78/1471	
HR (95%CI)		2.28 (1.53, 3.40)	1.66 (1.11, 2.28)	1.68 (1.06, 2.68)	
P trend			<0.001	0.006	0.006

Model 1: unadjusted model; Model 2: Adjusted for age and BMI; Model 3: further adjusted for HDL-C, TC, TG, hypertension, use of statins and family history of stroke

BMJ Open

Association between fasting blood glucose levels and stroke events: a large-scale community-based cohort study from China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050234.R1
Article Type:	Original research
Date Submitted by the Author:	13-Jul-2021
Complete List of Authors:	Zhang, Ya; Soochow University Medical College, School of Public Health Gu, Shujun; Changshu Center for Disease Control and Prevention Wang, Cuicui; Soochow University Medical College Liu, Dong; Soochow University Medical College Zhang, Qiuyi; Changshu Center for Disease Control and Prevention Yang, Man; Changshu Center for Disease Control and Prevention Zhou, Zhengyuan; Changshu Center for Disease Control and Prevention Zuo, Hui; Soochow University Medical College
Primary Subject Heading:	Public health
Secondary Subject Heading:	Epidemiology
Keywords:	Stroke < NEUROLOGY, DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **1 Association between fasting blood glucose levels and stroke**
5 **2 events: a large-scale community-based cohort study from China**
6
7
8
9

10 Ya Zhang ^{1,2,#}, Shujun Gu ^{3,#}, Cuicui Wang ^{1,2}, Dong Liu ^{1,2}, Qiuyi Zhang ³, Man
11 Yang ³, Zhengyuan Zhou ³, Hui Zuo ^{1,2,*}
12
13
14

15
16 ^a School of Public Health, Medical College of Soochow University, Suzhou 215123,
17
18 China
19

20 ^b Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric
21
22 Diseases, Medical College of Soochow University, Suzhou 215123, China
23

24 ^c Changshu Center for Disease Control and Prevention, Suzhou 215123, China
25

26 *# Ya Zhang and Shujun Gu contributed equally to this work.*
27
28

29
30 *** Corresponding Author:** Hui Zuo, School of Public Health, Medical College of
31
32 Soochow University, Suzhou, China, 199 Ren'ai Rd., Suzhou 215123, China. Email:
33
34 zuohui@suda.edu.cn.
35
36

37 **Running title:** Fasting blood glucose levels and stroke risk
38
39

40 **Word count:** 2753
41

42 **Number of Tables:** 4
43

44 **Number of Figures:** 1
45
46

47 **Disclosure of conflict of interest:** None
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 25 **Abstract**
5
6
7 26

8
9 27 **Objectives:** Diabetes mellitus has been associated with stroke. However, the
10
11 28 association between fasting blood glucose (FBG) and stroke risk in general population
12
13 29 remains still not clear. The purpose of our study was to examine the FBG levels on
14
15 30 subsequent stroke risk in a community-based cohort in China.
16

17 31
18
19 32 **Design:** Prospective cohort study, employing Cox proportional hazard model to
20
21 33 analyze the association of FBG levels with stroke risk.
22

23 34
24
25 35 **Setting:** A community-based cohort study included adults participating a baseline
26
27 36 survey conducted in 2013 in Changshu, eastern China.
28

29 37
30
31 38 **Participants:** 16,113 participants were recruited with a multi-stage sampling method,
32
33 39 excluding participants with severe disability, severe cancer, severe psychiatric
34
35 40 disturbance, or previous stroke before enrolment.
36

37 41
38 42 **Primary outcome measures:** Stroke events.
39

40 43
41
42 44 **Results:** During a median follow-up of 5.5 years, 417 incident cases of stroke were
43
44 45 identified. The adjusted HR for total and ischemic stroke for participants in the fourth
45
46 46 quartile of FBG compared with the first quartile was 1.44 (95% CI: 1.07, 1.94) and
47
48 47 1.57 (95% CI: 1.11, 2.21), respectively. FBG levels of ≥ 7.0 mmol/L was associated
49
50 48 with an increased risk of stroke based on two clinical classifications [ADA: 1.68
51
52 49 (1.24, 2.27); WHO: 1.62 (1.21, 2.13)]. In stratified analyses, risk associations existed
53
54 50 in women (HR: 1.92, 95% CI: 1.22, 3.01) and among postmenopausal women (HR:
55
56 51 1.68, 95% CI: 1.06-2.68) for the fourth quartile vs. the first. More importantly, the
57
58 52 meta-analysis observed a positive association between FBG levels and stroke risk
59
60 53 [pooled HR: 1.70, 95% CI: 1.27, 2.29; n=7)].

1
2
3
4 54

5 55 **Conclusions:** Higher FBG level was independently associated with an increased risk
6
7 56 of stroke in Chinese adults, especially significant in women.

8
9 57

10 58 **Keywords:** Stroke, Glucose, Risk, Cohort studies
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **59 Strengths and limitations of this study**

- 5
6 60 ● Large sample size, measurement of plasma FBG, and complete follow-up.
7
8 61 ● The meta-analysis based on 6 previously published studies and the current study
9
10 62 further confirmed the association between fasting blood glucose levels and stroke
11
12 63 risk.
13
14 64 ● No data available on HbA1c measurements in our study.
15
16 65

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

66 Introduction

67

68 Stroke is one of the most important causes of human diseases and death¹. According
69 to the statistics of global disease burden in 2013, about 25.7 million stroke patients
70 and 6.5 million stroke deaths worldwide². There are 113 million disability-adjusted
71 life years caused by stroke each year³. It poses a heavy psychological and economic
72 burden to patients' families and society. Therefore, the primary prevention of stroke
73 has now become a top priority for global public health. In China, it has become the
74 leading cause of death⁴ and one of the important reasons for disability in adults⁵.

75

76 Studies have shown that diabetes mellitus can increase the risk of stroke^{6,7}. A cohort
77 study involving 510,000 people observed that diabetes significantly increased the risk
78 of ischemic stroke and hematencephalon⁷. A prospective study showed that insulin
79 resistance or diagnosed diabetes can predict the first stroke⁸. However, these studies
80 focus on diabetes status instead of continuous glucose levels as the study exposure,
81 which limits the generalizability of the research findings. Since fasting blood glucose
82 (FBG) is the least interfered by diet⁹, the FBG levels are considered as a more reliable
83 tool to measure blood glucose levels than random blood glucose levels¹⁰. FBG levels
84 have a stronger predictive function for functional prognosis than random blood
85 glucose levels. Therefore, rather than focusing on random blood glucose, it is
86 important to explore the association between FBG levels and the risk of stroke.

87 In this study, a community population from China was followed up for 5.5 years to
88 study the relationship between FBG levels and the incidence of stroke, aiming at
89 providing suggestions and a basis for primary prevention of stroke among people with
90 different FBG levels.

91

92 **Methods**

93

94 **Study population**

95

96 The baseline survey of the current cohort study was conducted in 2013. The source
97 population was 20,343 participants aged 35-74 years in rural communities in
98 Changshu, eastern China who participated in an earlier study on metabolic syndrome
99 in 2008, in addition to a small proportion of new participants. A multi-stage sampling
100 method was used to recruit participants. Individuals with severe disability, severe
101 cancer, or a severe psychiatric disturbance were excluded. Of these, 16,457 subjects in
102 total were included in the baseline survey. We excluded 137 patients with a previous
103 stroke before enrolment. Participants with missing data on baseline health information
104 (n=207) were also excluded, leaving 16,113 participants in total for final analyses
105 (supplemental appendix S1).

106

107 **Laboratory measurements**

108

109 Blood samples were collected in the morning after overnight fasting and evaluated
110 biochemical and clinical parameters on the same day. FBG was measured by an
111 oxidase enzymatic method. The levels of high-density lipoprotein cholesterol (HDL-
112 C), total cholesterol (TC), and triglyceride (TG) were assessed enzymatically using
113 commercial reagents with an automatic biochemistry analyzer (Hitachi Inc, Tokyo,
114 Japan). The levels of low-density lipoprotein cholesterol (LDL-C) were calculated by
115 the Friedewald formula¹¹. The estimated glomerular filtration rate (eGFR) was
116 calculated on the basis of the chronic kidney disease-epidemiology creatinine
117 equation¹².

118

119 **Follow-up and ascertainment of stroke**

120

1
2
3
4 121 Follow-up began at the baseline and ended at the date of stroke diagnosis, death, or
5
6 122 December 31, 2018, whichever came first. We classified total stroke into an ischemic
7
8 123 stroke, and non-ischemic stroke (including hemorrhagic stroke, subarachnoid
9
10 124 hemorrhage, and unexplained types of stroke). The primary outcome was
11
12 125 hospitalization or death due to stroke collected by ICD-10 codes (total stroke: I60-I61,
13
14 126 I63-I64; ischemic stroke: 63 except I63.9). If a participant had more than 1 stroke
15
16 127 event during the follow-up, only the first stroke was considered.
17
18 128

129 **Assessments of covariates**

130
131 Demographic characteristics, lifestyle factors, personal medical history [CVD,
132 hyperlipidemia, hypertension, diabetes, chronic obstructive pulmonary disease
133 (COPD), nephropathy, and cancer], and family history data for all participants were
134 obtained using standard questionnaires administered by trained staff. After the
135 subjects rested for 5 minutes, the trained observers used an electronic
136 sphygmomanometer (Omron Hp1300, OMRON Corporation, China) to measure the
137 blood pressure in the sitting position three times every 30 seconds. The criteria for
138 defining hypertension were an average measurement of systolic blood pressure \geq
139 140mmHg or diastolic blood pressure \geq 90mmHg¹³, diagnosis of hypertension, or
140 antihypertensive medication. Impaired fasting glucose (IFG) is defined as an FBG of
141 6.1-6.9 mmol/L by WHO¹⁴ and an FBG of 5.6-6.9 mmol/L by the American Diabetes
142 Association (ADA)¹⁵. The body mass index (BMI) was calculated as weight in
143 kilograms divided by the square of height in meters, among weight and height were
144 measured by standard methods¹⁶.

146 **Meta-analysis**

147
148 We conducted a meta-analysis combining the current study findings with previous
149 observations on FBG and stroke risk. We searched PubMed, Web of Knowledge,
150 medRxiv, and bioRxiv databases for related research articles published between

1
2
3
4 151 January 01, 2000-September 10, 2020 using the keywords “stroke”, “cardiovascular
5 152 disease” and “fasting blood glucose”, “blood glucose”, “fasting glucose”, “fasting
6 153 plasma glucose”, “glucose”, in addition to “prospective study”, “cohort study”, or
7 154 “follow-up”. The study subjects were restricted to apparently healthy adults in the
8 155 community. Two authors extracted the data independently, and if they had
9 156 disagreements, discussed it with the third author. This study was conducted following
10 157 the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
11 158 guideline. Finally, seven studies were included¹⁷⁻²². We extracted information about
12 159 authors, sample size, the country where the study was implemented, time of follow-
13 160 up, adjusted covariates, outcome (stroke events), and the effect size [hazard ratio
14 161 (HR)]. The measurement and definition of FBG levels were directly extracted from
15 162 each literature. We used a random-effect model to calculate the pooled risk estimation
16 163 based on the assumption of study heterogeneity. The Begg and Egger tests were
17 164 performed to detect potential publication bias²³.

165 166 **Statistical analysis**

167
168 Baseline demographic characteristics for continuous variables were expressed as
169 median (interquartile ranges), and categorical variables were presented as
170 percentages. Log-transformation was used to all laboratory measures to normalize
171 distributions.

172
173 Cox proportional hazard analyses were conducted to evaluate FBG levels and risk of
174 stroke and results presented as HR and 95% confidence intervals (CI). FBG levels
175 were included in the models as a categorical measure (quartiles and three categories
176 by clinical criteria). Multivariable models included conventional risk factors at
177 baseline: age (continuous), sex, BMI (continuous), current smoking (yes/no), family
178 history of stroke (yes/no), hypertension (yes/no), eGFR(ml/min/1.73m²) LDL-C
179 (mmol/L), HDL-C (mmol/L), TC (mmol/L), TG (mmol/L) and use of statins. We also
180 used clinical classification (normal FBG, IFG, hyperglycemia) to classify FBG levels.

1
2
3
4 181 In addition, we conducted stratified analyses by sex to check potential effect
5
6 182 modification. Sensitivity analyses were conducted to determine the robustness of the
7
8 183 primary analysis results. We limited the risk-association analyses to participants who
9
10 184 didn't report their own medical history, including hypertension, hyperlipidemia,
11
12 185 cancer, nephropathy, CVD, or COPD at baseline.

13
14 186

15 187 Statistical analyses were conducted with R (version 4.0.2, www.r-project.org). All
16
17 188 tests were 2-sided, and a P value less than 0.05 was considered statistically
18
19 189 significant.

20
21 190

22
23 191

24 25 192 **Patient and public involvement**

26
27 193

28
29 194 Patients and the public were not involved in the design, conduct, or reporting of this
30
31 195 study.

196 **Results**

197

198 **Characteristics of the study population**

199

200 After a median follow-up of 5.5 years (range: 0.1-5.7 years), a total of 417 (192 men
201 and 225 women) stroke events were identified, of which 323 (77.5%) were ischemic
202 stroke. Table 1 shows the baseline characteristics of participants across the quartiles
203 of FBG. Compared with the participants in the study with lower FBG, those with
204 higher FBG levels were more likely to suffer from obesity, hypertension, and
205 hyperlipidemia, had lower levels of eGFR, and preferred to have a family history of
206 stroke ($P<0.001$, Table 1).

207

208 **FBG levels and risk of stroke**

209

210 As shown in Table 2, we observed that higher FBG levels were significantly
211 correlated with an increased risk of total and ischemic stroke in both the original
212 models and models adjusted for age, sex, BMI, HDL-C, LDL-C, TC, TG, eGFR,
213 hypertension, smoking status, use of statins and family history of stroke. Compared to
214 the lowest FBG quartile, the multivariable-adjusted HRs for the highest quartile were
215 1.44 (95% CI: 1.07-1.94, $P=0.021$) for total and 1.57 (95%CI: 1.11-2.21, $P=0.016$) for
216 ischemic stroke. A positive association between FBG levels and non-ischemic stroke
217 was observed in the crude model, but the risk association was rendered statistically
218 nonsignificant in adjusted models. Further, we examined the association between
219 clinical classifications of FBG levels and stroke risk, and the results are presented in
220 Table 3. The multivariable-adjusted HR for total stroke was 1.68 (95%CI: 1.24-2.27,
221 $P=0.001$) and 1.62 (95% CI: 1.21-2.13, $P=0.002$) for participants with hyperglycemia
222 compared with those with normal blood glucose, following the ADA and WHO
223 recommendations, respectively.

224

1
2
3
4 225 Results of sex-stratified analyses are shown in Table 4. In original models, higher
5
6 226 levels of FBG were significantly associated with an increased risk of total stroke only
7
8 227 in women. After adjustment covariate for age, BMI, and other variates, the risk
9
10 228 association remained significant (HR: 1.92, 95%CI: 1.22-3.01, P=0.004) for the
11
12 229 fourth level in female groups. Similar risk estimates were found in postmenopausal or
13
14 230 oophorectomy women. But no significant association with stroke was observed for
15
16 231 FBG levels in premenopausal women (supplemental appendix S2).

17
18 232

19 233 In sensitivity analyses, the study population was restricted to 15,404 subjects without
20
21 234 a self-reported history of hyperlipidemia, CVD, cancer, nephropathy, and COPD
22
23 235 yielded essentially no change in risk of total stroke (HR: 1.38, 95% CI: 1.01, 1.92)
24
25 236 and ischemic stroke (HR: 1.55, 95% CI: 1.06, 2.26). Additional eliminated for
26
27 237 participants with hypertension, the association in women was slightly raised for total
28
29 238 stroke (HR: 2.50, 95% CI: 1.11, 5.60) and ischemic stroke (HR: 2.59, 95% CI: 1.03,
30
31 239 6.51) (data not shown).

32
33 240

34 241 **Meta-analysis**

35
36 242

37
38 243 Figure 1 shows the results of meta-analysis including six previously published
39
40 244 prospective studies together with our current study. In a word, higher FBG levels
41
42 245 were associated with an increased risk of stroke (pooled HR: 1.70, 95% CI: 1.27-
43
44 246 2.29). The Begg and Egger tests didn't suggest existence of potential publication bias
45
46 247 (P>0.1 for both tests).

249 **Discussion**

250

251 **Principal findings**

252

253 In our prospective community-based cohort, higher FBG levels were associated with
254 an increased risk of total and ischemic stroke. The risk-association was prominent in
255 women. After excluding the baseline of hypertension, hyperlipidemia, CVD, cancer,
256 nephropathy, and COPD, these associations were still persisted in analyses of women.
257 Our findings extend the previous knowledge on diabetes and stroke risk, suggesting
258 an important role of routine glucose measurement in stroke prevention.

259

260 **Associations of FBG with stroke risk**

261

262 When analyzing stroke subtypes, there is no evidence that FBG is associated with
263 non-ischemic stroke, but the association with ischemic stroke persists. This is
264 consistent with the results of a prospective cohort study among Korean men¹⁴. It
265 suggests that the correlation between FBG and stroke is mainly contributed by an
266 ischemic stroke. A large-scale prospective study in China (including 96,110
267 participants) indicated that both hyperglycemia and hypoglycemia are associated with
268 an increased risk of incident intracerebral hemorrhage, after adjustment for potential
269 confounders²⁴.

270

271 Results based on the ADA and WHO criteria demonstrated that FBG levels of ≥ 7.0
272 mmol/L were a significant risk factor for stroke [HR (95% CI): 1.68 (1.24, 2.27) and
273 1.62 (1.21, 2.13) following the ADA and WHO criteria, respectively], whereas the
274 risk of stroke in patients with IFG had an increase trend but this trend was not
275 statistically significant. A large number of studies showed that people with diabetes
276 are at increased risk of ischemic stroke^{25 26}. A meta-analysis including 698,782
277 participants reported that the risk of ischemic stroke in diabetic patients was 2.27

1
2
3
4 278 times higher than normal people²⁵. A cohort study in Swedish also showed that poor
5
6 279 blood glucose control in patients with type 2 diabetes was associated with an
7
8 280 increased risk of stroke and death²⁶. Although diabetes is associated with stroke, the
9
10 281 influence of prediabetes on future stroke risk has not been clear yet. Some large
11
12 282 sample meta-analyses reported prediabetes is associated with the risk of CVD^{27 28} and
13
14 283 heart failure²⁹. But in another meta-analysis including 15 cohort studies, more than
15
16 284 half of the studies showed that after adjusting for cardiovascular risk factors, there
17
18 285 was no significant association between pre-diabetes and stroke³⁰. A cohort study
19
20 286 investigated the sex-specific associations of pre-diabetes with major clinical outcomes
21
22 287 reached the same conclusion³¹.

23
24 288
25
26 289 Stratified analysis showed that the correlation between FBG levels and stroke risk
27
28 290 only existed in women. According to the re-stratification of menopause, only
29
30 291 postmenopausal women with the highest FBG level had a higher risk of stroke [HR
31
32 292 (95% CI): 1.68 (1.06, 2.68)], no associations were found in premenopausal women. It
33
34 293 probably due to the low number of stroke events in premenopausal women. Few
35
36 294 published studies reported sex-stratified results. A sex-specific cohort study in the
37
38 295 Middle East showed that only men with higher FBG levels showed an increased risk
39
40 296 of stroke [HR: 2.15(1.26, 4.67) in FBG level of 6.1-6.9 mmol/L, HR: 2.38 (1.08, 5.25)
41
42 297 in FBG level of >7.0 mmol/L]³². Korean Heart Study showed that IFG was associated
43
44 298 with an increased risk of ischemic stroke in men but not in women³³. We suspect that
45
46 299 the disparities in sex between studies could be due to different definitions of outcome
47
48 300 (all stroke vs. ischemic stroke) and the variety in covariate adjustments. A meta-
49
50 301 analysis including 64 cohort studies provides the clearest evidence yet for the sex
51
52 302 difference of diabetes and stroke risk. The excess risk of diabetes-related stroke in
53
54 303 women is significantly higher than that in men and independent of sex-difference in
55
56 304 other cardiovascular risk factors³⁴. Our results support the findings of this meta-
57
58 305 analysis, indicating that the association between FBG levels and stroke cases in
59
60 306 women, and the mechanism may be related to the protective effect of estrogen.

307

308 Possible mechanisms

309

310 Accumulating evidence suggests that FBG levels can be used to predict the risk of
311 CVD^{20 25 35}. As an adverse consequence of CVD, stroke is closely related to FBG
312 levels^{36 37}. Its mechanism may be related to the dysfunction of cerebral
313 microvasculature caused by hyperglycemia, insulin resistance, obesity, and
314 hypertension³⁸. The microvasculature is involved in the regulation of many brain
315 processes. Once damaged, it's easy to cause cerebrovascular accidents³⁹. The
316 dysfunction is also obvious in the prediabetes population, which may suggest that IFG
317 is the risk factor for stroke⁴⁰. Besides, diabetic retinopathy was proved to be a sign of
318 lacunar ischemic stroke, which had the same effects as cerebral microvascular
319 dysfunction⁴¹.

320

321 Compared with men, women with diabetes are at higher risk of stroke³⁴. Previously, it
322 was thought that the sex specificity of the severity of diabetes-related cardiovascular
323 diseases was caused by the differences between men and women in treatment and
324 chronic disease management. However, as the gradual equality of men and women,
325 the risk of serious cardiovascular disease in postmenopausal women is still higher³⁴.
326 Sex hormones may explain the sex differences observed in human epidemiological
327 studies⁴²⁻⁴⁴, indicating the estrogen protection in women, preventing the progression
328 of non-diabetic cardiovascular diseases at least before menopause. Animal
329 experiments show that the decrease of estrogen levels in ovariectomized mice can
330 lead to impaired glycemia, reduced glucose tolerance, hyperinsulinemia, and impaired
331 insulin secretion, and then develop into hyperglycemia and atherosclerosis⁴⁵.
332 However, diabetes seemingly attenuates the protective effect of estrogen on women in
333 the development of CVD⁴⁶.

334

335 Strengths and Limitations

336

1
2
3
4 337 The main strengths of this study include the large sample size, measurement of
5
6 338 plasma FBG, and the complete follow-up. We followed up the cases by recording
7
8 339 linkages with hospital discharge diagnoses and the Cause of Death Registry. We used
9
10 340 both quartiles and clinical classifications (normal FBG, IFG, hyperglycemia) to
11
12 341 classify FBG levels, and obtained similar results. We considered different stroke
13
14 342 subtypes as the study outcome. To our knowledge, this study provides the first meta-
15
16 343 analysis investigating the association between FBG levels and stroke risk in the
17
18 344 general population, therefore results are likely generalizable to all races.
19

20 345

21 346 Our study has several limitations. First, we do not have HbA_{1c} measurements in this
22
23 347 study. Among indicators to assess glucose variability, HbA_{1c} is the gold standard for
24
25 348 clinical evaluation of long-term blood glucose control⁸, while FBG may overlook the
26
27 349 potential effects of postprandial blood glucose levels and other meaningful factors⁴⁷.
28
29 350 Reports revealed that HbA_{1c} played an important role in distinguishing people with
30
31 351 high cardiovascular risk from those without diabetes^{48 49}. Second, the levels of
32
33 352 estradiol and testosterone in the study subjects were not measured, although we
34
35 353 speculated that the sex difference was probably due to the protective effect of sex
36
37 354 hormone. Third, due to a low number of stroke cases, the real risk association of the
38
39 355 premenopausal population may be biased.

40
41 356
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 357 **Conclusions**

5
6 358

7
8
9 359 Our study indicates that higher FBG levels are associated with an increased stroke in
10 360 the general population, and meta-analysis corroborated this finding. Further, we
11
12 361 observed that the association was more prominent in women than in men. We also
13
14 362 observed strong risk associations among postmenopausal or oophorectomy women.
15
16 363 FBG levels as a routine and low-cost measurement could be used to identify
17
18 364 individuals with higher stroke risk in the future.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **365 Contributors**

5
6
7 366

8
9 367 Conceptualization, YZ and HZ; methodology, YZ; software, YZ; validation, YZ;
10 368 formal analysis, YZ; resources, SG, QZ, MY and ZZ; data curation, YZ; visualization,
11 369 YZ; investigation, YZ, CW and DL; writing—original draft preparation, YZ and SG;
12 370 writing—review and editing, YZ and HZ; supervision, HZ; project administration,
13 371 HZ; funding acquisition, SG and HZ. All authors have agreed on the journal to which
14 372 the article has been submitted and agreed to be accountable for all aspects of the
15 373 work. All authors read and approved the final manuscript.

16
17
18
19
20
21
22 374

23
24
25 **375 Funding**

26
27 376

28
29 377 This work was supported by the National Natural Science Foundation of China [Nos.
30 378 81973122].

31
32
33 379

34
35 **380 Competing interests**

36
37
38 381

39
40 382 None declared.

41
42 383

43
44 **384 Patient consent for publication**

45
46
47 385

48
49 386 Not required.

50
51 387

52
53 **388 Ethics approval**

54
55
56 389

57
58 390 The study protocol conforms to the ethical guidelines of the Declaration of Helsinki.

59
60 391 The baseline survey and record linkages with study outcomes were approved by the

1
2
3
4 392 Ethics Committee of Fuwai Cardiovascular Hospital, Beijing, China (No. 2012-399).

5 393 After a detailed explanation of our study, we obtained a written informed consent

6
7 394 form from each participant.

8
9 395

10
11 396 **Provenance and peer review**

12
13
14 397

15
16 398 Not commissioned; externally peer reviewed.

17
18 399

19
20 400 **Data availability statement**

21
22
23 401

24
25 402 The datasets generated and/or analyzed during the current study are not publicly

26
27 403 available due to the restrictions of containing information that could compromise the

28
29 404 privacy of research participants.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

405 **References**

406

- 407 1. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188
408 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease
409 Study 2013. *Lancet Neurol* 2016;15(9):913-24. doi: 10.1016/S1474-4422(16)30073-4.
- 410 2. Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. *Circ Res* 2017;120(3):439-48.
411 doi: 10.1161/CIRCRESAHA.116.308413.
- 412 3. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of Ischemic
413 and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. *Neuroepidemiology*
414 2015;45(3):161-76. doi: 10.1159/000441085.
- 415 4. Wang W, Jiang B, Sun H, et al. Prevalence, Incidence, and Mortality of Stroke in China:
416 Results from a Nationwide Population-Based Survey of 480 687 Adults. *Circulation*
417 2017;135(8):759-71. doi: 10.1161/CIRCULATIONAHA.116.025250.
- 418 5. Liu LP, Wong LK, Wang DZ, et al. Current status of endovascular procedures in
419 management of ischemic stroke in China. *CNS Neurosci Ther* 2014;20(6):483-4. doi:
420 10.1111/cns.12281.
- 421 6. Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the
422 Northern Manhattan Study. *Stroke* 2012;43(5):1212-7. doi:
423 10.1161/STROKEAHA.111.641381.
- 424 7. Bragg F, Li L, Yang L, et al. Risks and Population Burden of Cardiovascular Diseases
425 Associated with Diabetes in China: A Prospective Study of 0.5 Million Adults. *PLoS*
426 *Med* 2016;13(7):e1002026. doi: 10.1371/journal.pmed.1002026.
- 427 8. Jia Z, Wu S, Zhou Y, et al. Metabolic syndrome and its components as predictors of stroke

- 1
2
3
4 428 in middle-aged and elderly Chinese people. *Neurol Res* 2011;33(5):453-9. doi:
5
6
7 429 10.1179/016164111X13007856083882.
8
9 430 9. Moebus S, Gores L, Losch C, et al. Impact of time since last caloric intake on blood
10
11 431 glucose levels. *Eur J Epidemiol* 2011;26(9):719-28. doi: 10.1007/s10654-011-9608-z.
12
13
14 432 10. Morris HJDC. Standards of Medical Care in Diabetes. 2014;36(Suppl 1):S11-S66.
15
16
17 433 11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density
18
19 434 lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin*
20
21 435 *Chem* 1972;18(6):499-502.
22
23
24 436 12. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration
25
26 437 rate. *Ann Intern Med* 2009;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-
27
28 438 00006.
29
30
31 439 13. Clinical WHOJ, Hypertension E. International Society of Hypertension Guidelines for the
32
33 440 Management of Hypertension. Guidelines Subcommittee. 1999;21(5-6):1009-60.
34
35
36 441 14. Organization WH. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus:
37
38 442 abbreviated report of a WHO consultation: World Health Organization, 2011.
39
40
41 443 15. American Diabetes A. Standards of Medical Care in Diabetes-2020 Abridged for Primary
42
43 444 Care Providers. *Clin Diabetes* 2020;38(1):10-38. doi: 10.2337/cd20-as01.
44
45
46 445 16. Kok P, Seidell JC, Meinders AE. [The value and limitations of the body mass index (BMI)
47
48 446 in the assessment of the health risks of overweight and obesity]. *Ned Tijdschr*
49
50 447 *Geneeskd* 2004;148(48):2379-82.
51
52
53 448 17. Nielson C, Fleming RM. Blood glucose and cerebrovascular disease in nondiabetic
54
55 449 patients. *Angiology* 2007;58(5):625-9. doi: 10.1177/0003319707303695.
56
57
58
59
60

- 1
2
3
4 450 18. Boden-Albala B, Cammack S, Chong J, et al. Diabetes, fasting glucose levels, and risk of
5
6 451 ischemic stroke and vascular events: findings from the Northern Manhattan Study
7
8
9 452 (NOMAS). *Diabetes Care* 2008;31(6):1132-7. doi: 10.2337/dc07-0797.
10
11
12 453 19. Sung J, Song YM, Ebrahim S, et al. Fasting blood glucose and the risk of stroke and
13
14 454 myocardial infarction. *Circulation* 2009;119(6):812-9. doi:
15
16
17 455 10.1161/CIRCULATIONAHA.108.776989.
18
19
20 456 20. Liu F, Yang X, Li J, et al. Association of fasting glucose levels with incident atherosclerotic
21
22 457 cardiovascular disease: An 8-year follow-up study in a Chinese population. *J*
23
24 458 *Diabetes* 2017;9(1):14-23. doi: 10.1111/1753-0407.12380.
25
26
27 459 21. Lee G, Kim SM, Choi S, et al. The effect of change in fasting glucose on the risk of
28
29 460 myocardial infarction, stroke, and all-cause mortality: a nationwide cohort study.
30
31 461 *Cardiovasc Diabetol* 2018;17(1):51. doi: 10.1186/s12933-018-0694-z.
32
33
34 462 22. Peng X, Ge J, Wang C, et al. Longitudinal Average Glucose Levels and Variance and
35
36 463 Risk of Stroke: A Chinese Cohort Study. *Int J Hypertens* 2020;2020:8953058. doi:
37
38 464 10.1155/2020/8953058.
39
40
41 465 23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication
42
43 466 bias. *Biometrics* 1994;50(4):1088-101.
44
45
46 467 24. Jin C, Li G, Rexrode KM, et al. Prospective Study of Fasting Blood Glucose and
47
48 468 Intracerebral Hemorrhagic Risk. *Stroke* 2018;49(1):27-33. doi:
49
50 469 10.1161/STROKEAHA.117.019189.
51
52
53 470 25. Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose
54
55 471 concentration, and risk of vascular disease: a collaborative meta-analysis of 102
56
57
58
59
60

- 1
2
3
4 472 prospective studies. *Lancet* 2010;375(9733):2215-22. doi: 10.1016/S0140-
5
6 473 6736(10)60484-9.
7
8
9 474 26. Zabala A, Darsalia V, Holzmann MJ, et al. Risk of first stroke in people with type 2
10
11 475 diabetes and its relation to glycaemic control: A nationwide observational study.
12
13 476 *Diabetes Obes Metab* 2020;22(2):182-90. doi: 10.1111/dom.13885.
14
15
16
17 477 27. Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause
18
19 478 mortality and cardiovascular disease: updated meta-analysis. *BMJ* 2020;370:m2297.
20
21 479 doi: 10.1136/bmj.m2297.
22
23
24 480 28. Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular
25
26 481 disease and all cause mortality: systematic review and meta-analysis. *BMJ*
27
28 482 2016;355:i5953. doi: 10.1136/bmj.i5953.
29
30
31 483 29. Cai X, Liu X, Sun L, et al. Prediabetes and the risk of heart failure: A meta-analysis.
32
33 484 *Diabetes Obes Metab* 2021 doi: 10.1111/dom.14388.
34
35
36
37 485 30. Lee M, Saver JL, Hong KS, et al. Effect of pre-diabetes on future risk of stroke: meta-
38
39 486 analysis. *BMJ* 2012;344:e3564. doi: 10.1136/bmj.e3564.
40
41
42 487 31. Shang Y, Fratiglioni L, Marseglia A, et al. Association of diabetes with stroke and post-
43
44 488 stroke dementia: A population-based cohort study. *Alzheimers Dement*
45
46 489 2020;16(7):1003-12. doi: 10.1002/alz.12101.
47
48
49
50 490 32. Parizadeh D, Rahimian N, Akbarpour S, et al. Sex-specific clinical outcomes of impaired
51
52 491 glucose status: A long follow-up from the Tehran Lipid and Glucose Study. *Eur J Prev*
53
54 492 *Cardiol* 2019;26(10):1080-91. doi: 10.1177/2047487319834396.
55
56
57
58 493 33. Kim HK, Kim CH, Kim EH, et al. Impaired fasting glucose and risk of cardiovascular
59
60

- 1
2
3
4 494 disease in Korean men and women: the Korean Heart Study. *Diabetes Care*
5
6 495 2013;36(2):328-35. doi: 10.2337/dc12-0587.
7
8
9 496 34. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women
10
11 497 compared with men: a systematic review and meta-analysis of 64 cohorts, including
12
13 498 775,385 individuals and 12,539 strokes. *Lancet* 2014;383(9933):1973-80. doi:
14
15 499 10.1016/S0140-6736(14)60040-4.
16
17
18
19 500 35. Bragg F, Li L, Smith M, et al. Associations of blood glucose and prevalent diabetes with
20
21 501 risk of cardiovascular disease in 500 000 adult Chinese: the China Kadoorie Biobank.
22
23 502 *Diabet Med* 2014;31(5):540-51. doi: 10.1111/dme.12392.
24
25
26
27 503 36. Luitse MJ, Biessels GJ, Rutten GE, et al. Diabetes, hyperglycaemia, and acute ischaemic
28
29 504 stroke. *Lancet Neurol* 2012;11(3):261-71. doi: 10.1016/S1474-4422(12)70005-4.
30
31
32 505 37. Liu J, Rutten-Jacobs L, Liu M, et al. Causal Impact of Type 2 Diabetes Mellitus on
33
34 506 Cerebral Small Vessel Disease: A Mendelian Randomization Analysis. *Stroke*
35
36 507 2018;49(6):1325-31. doi: 10.1161/STROKEAHA.117.020536.
37
38
39 508 38. van Sloten TT, Sedaghat S, Carnethon MR, et al. Cerebral microvascular complications of
40
41 509 type 2 diabetes: stroke, cognitive dysfunction, and depression. *Lancet Diabetes*
42
43 510 *Endocrinol* 2020;8(4):325-36. doi: 10.1016/S2213-8587(19)30405-X.
44
45
46
47 511 39. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical
48
49 512 implications. *Lancet Neurol* 2019;18(7):684-96. doi: 10.1016/S1474-4422(19)30079-
50
51 513 1.
52
53
54
55 514 40. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With
56
57 515 Widespread Consequences. *Diabetes* 2018;67(9):1729-41. doi: 10.2337/dbi17-0044.
58
59
60

- 1
2
3
4 516 41. Hankey GJ, Anderson NE, Ting RD, et al. Rates and predictors of risk of stroke and its
5
6 517 subtypes in diabetes: a prospective observational study. *J Neurol Neurosurg*
7
8
9 518 *Psychiatry* 2013;84(3):281-7. doi: 10.1136/jnnp-2012-303365.
10
11
12 519 42. Brann DW, Dhandapani K, Wakade C, et al. Neurotrophic and neuroprotective actions of
13
14 520 estrogen: basic mechanisms and clinical implications. *Steroids* 2007;72(5):381-405.
15
16
17 521 doi: 10.1016/j.steroids.2007.02.003.
18
19
20 522 43. Howard VJ, Madsen TE, Kleindorfer DO, et al. Sex and Race Differences in the
21
22 523 Association of Incident Ischemic Stroke With Risk Factors. *JAMA Neurol*
23
24 524 2019;76(2):179-86. doi: 10.1001/jamaneurol.2018.3862.
25
26
27 525 44. Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology,
28
29
30 526 clinical presentation, medical care, and outcomes. *Lancet Neurol* 2008;7(10):915-26.
31
32 527 doi: 10.1016/S1474-4422(08)70193-5.
33
34
35 528 45. Venegas-Pino DE, Wang PW, Stoute HK, et al. Sex-Specific Differences in an ApoE(-
36
37 529 /-):Ins2(+)/Akita) Mouse Model of Accelerated Atherosclerosis. *Am J Pathol*
38
39 530 2016;186(1):67-77. doi: 10.1016/j.ajpath.2015.09.009.
40
41
42
43 531 46. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk,
44
45 532 Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev*
46
47 533 2016;37(3):278-316. doi: 10.1210/er.2015-1137.
48
49
50 534 47. Jia Q, Zheng H, Zhao X, et al. Abnormal glucose regulation in patients with acute stroke
51
52 535 across China: prevalence and baseline patient characteristics. *Stroke*
53
54 536 2012;43(3):650-7. doi: 10.1161/STROKEAHA.111.633784.
55
56
57
58 537 48. Di Pino A, Mangiafico S, Urbano F, et al. HbA1c Identifies Subjects With Prediabetes and
59
60

- 1
2
3
4 538 Subclinical Left Ventricular Diastolic Dysfunction. *J Clin Endocrinol Metab*
5
6 539 2017;102(10):3756-64. doi: 10.1210/jc.2017-00954.
7
8
9 540 49. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular
10
11 541 risk in nondiabetic adults. *N Engl J Med* 2010;362(9):800-11. doi:
12
13 542 10.1056/NEJMoa0908359.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 544 **Figure 1.** Meta-analysis of fasting blood glucose at the highest vs lowest levels and the
5 545 risk of developing stroke. The horizontal lines indicate the lower and upper limits of
6
7 546 the 95% CI, and the grey squares reflects the HR of each study. HR: Hazard Ratio.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Baseline characteristics of study population by FBG levels and stroke risk: Cohort Changshu.

Characteristic	Total	Quartile of FBG Levels (mmol/L)				P Value
	n=16,113	Q1 (< 4.87) n=4097	Q2 (4.87-5.24) n=4027	Q3 (5.24-5.77) n=3979	Q4 (> 5.77) n=4010	
Age, yrs	55.7 (46.3, 64.4)	48.6 (41.4, 59.1)	53.8 (44.8, 62.84)	57.8 (48.6, 65.9)	60.0 (51.4, 67.2)	<0.001
Men (%)	40.9	42.1	39.4	40.2	42.1	0.002
Premenopausal in women (%)	37.5	55.3	42.3	29.7	22.3	<0.001
Follow-up time, yrs	5.53 (5.49, 5.56)	5.52 (5.49, 5.54)	5.52 (5.49, 5.55)	5.53 (5.50, 5.57)	5.55 (5.50, 5.58)	<0.001
BMI (kg/m ²)	23.3 (21.2, 25.7)	22.6 (20.6, 24.9)	23.0 (21.0, 25.3)	23.6 (21.5, 25.9)	24.2 (22.0, 26.5)	<0.001
Current smoking (%)	23.6	26.9	23.5	21.9	21.9	<0.001
Family history of stroke (%)	5.8	3.8	5.4	6.5	7.6	<0.001
Hypertension (%)	22.8	13.9	18.6	24.9	34.0	<0.001
Fasting blood glucose, mmol/L	5.24 (4.87, 5.77)	4.66 (4.47, 4.77)	5.06 (4.97, 5.15)	5.47 (5.34, 5.60)	6.37 (6.01, 7.20)	<0.001
impaired fasting glucose (%)	8.6	—	—	—	34.7	<0.001
Diabetes (%)	8.8	0.6	0.7	1.0	33.3	<0.001
TC, mmol/L	4.70 (4.13, 5.36)	4.48 (3.95, 5.04)	4.62 (4.08, 5.23)	4.79 (4.22, 5.44)	4.99 (4.36, 5.70)	<0.001
TG, mmol/L	1.32 (0.96, 1.90)	1.20 (0.88, 1.68)	1.26 (0.93, 1.78)	1.33 (0.97, 1.91)	1.52 (1.08, 2.30)	<0.001
HDL-C, mmol/L	1.38 (1.14, 1.66)	1.36 (1.14, 1.62)	1.37 (1.14, 1.64)	1.40 (1.15, 2.68)	1.38 (1.14, 1.69)	<0.001
LDL-C, mmol/L	2.57 (1.92, 3.27)	2.64 (2.03, 3.34)	2.62 (1.97, 3.30)	2.55 (1.89, 3.26)	2.47 (1.79, 3.17)	<0.001
eGFR (ml/min/1.73m ²)	95.59 (84.39, 105.42)	100.88 (89.80, 110.06)	96.744 (86.38, 106.50)	93.60 (83.12, 102.95)	91.65 (79.13, 101.17)	<0.001
Use of statins (%)	0.4	0.1	0.3	0.3	0.7	<0.001

¹ BMI, body mass index; HDL-C, high density lipoprotein cholesterol; Q, quartile; TC, total cholesterol; TG, triglyceride.

² P Values were determined by Chi-square tests for categorical and Kruskal-Wallis tests for continuous variables.

Table 2. Hazard ratios (95% CI) for incident stroke by FBG quartiles

		Quartile of FBG Levels				P trend
		Q1	Q2	Q3	Q4	
		HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	
Total stroke	Cases/N	57/4097	89/4027	110/3979	161/4010	
	Model 1	1 (Ref.)	1.60 (1.15, 2.22)	2.00 (1.45, 2.75)	2.92 (2.16, 3.94)	<0.001
	Model 2	1 (Ref.)	1.21 (0.87, 1.69)	1.17 (0.85, 1.62)	1.46 (1.07, 1.98)	0.018
	Model 3	1 (Ref.)	1.19 (0.86, 1.63)	1.16 (0.86, 1.62)	1.44 (1.07, 1.94)	0.021
Ischemic stroke	Cases/N	42/4097	69/4027	83/3979	129/4010	
	Model 1	1 (Ref.)	1.68 (1.15, 2.47)	2.05 (1.41, 2.96)	3.17 (2.24, 4.49)	<0.001
	Model 2	1 (Ref.)	1.27 (0.87, 1.87)	1.19 (0.82, 1.73)	1.58 (1.11, 2.25)	0.013
	Model 3	1 (Ref.)	1.25 (0.91, 1.86)	1.17 (0.81, 1.70)	1.57 (1.11, 2.21)	0.016
Non-ischemic stroke	Cases/N	15/4097	20/4027	27/3979	32/4010	
	Model 1	1 (Ref.)	1.36 (0.70, 2.66)	1.86 (0.99, 3.50)	2.20 (1.19, 4.07)	0.006
	Model 2	1 (Ref.)	1.04 (0.53, 2.04)	1.13 (0.60, 2.14)	1.11 (0.59, 2.07)	0.713
	Model 3	1 (Ref.)	1.10 (0.57, 2.14)	1.12 (0.64, 2.24)	1.07 (0.57, 1.99)	0.844

Model 1: unadjusted model; Model 2: adjusted for age, sex and BMI; Model 3: further adjusted for HDL-C, TC, TG, LDL-C, eGFR, hypertension, smoking status, use of statins and family history of stroke.

Table 3. Hazard ratios (95% CI) for incident stroke by clinical classifications of FBG levels

			Model 1	Model 2	Model 3
ADA definition	<5.6 mmol/L	Cases/N		220/11079	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	5.6–6.9 mmol/L	Cases/N		136/3869	
		HR (95%CI)	1.78 (1.43, 2.20)	1.16 (0.94, 1.44)	1.17 (0.93, 1.42)
	≥7.0 mmol/L	Cases/N		61/1165	
		HR (95%CI)	2.69 (2.02, 3.57)	1.72 (1.29, 2.28)	1.68 (1.24, 2.27)
P trend			<0.001	0.001	0.001
WHO definition	<6.1 mmol/L	Cases/N		301/13422	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	6.1–6.9 mmol/L	Cases/N		55/1526	
		HR (95%CI)	1.61 (1.21, 2.15)	1.08 (0.81, 1.45)	1.11 (0.83, 1.47)
	≥7.0 mmol/L	Cases/N		61/1165	
		HR (95%CI)	2.38 (1.81, 3.03)	1.64 (1.24, 2.17)	1.62 (1.21, 2.13)
P trend			<0.001	0.001	0.002


ADA: American Diabetes Association; WHO: World Health Organization.

Model 1: unadjusted model; Model 2: adjusted for age, sex and BMI; Model 3: further adjusted for HDL-C, TC, TG, LDL-C, eGFR, hypertension, smoking status, use of statins and family history of stroke.


Table 4. Hazard ratios (95% CI) for incident stroke by sex

		Quartile of FBG Levels				P trend
		Q1	Q2	Q3	Q4	
		HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	
	Cases/N	33/1725	42/1586	53/1599	64/1688	
Men	Model 1	1 (Ref.)	1.40 (0.89, 2.20)	1.74 (1.13, 2.69)	1.99 (1.31, 3.03)	0.001
	Model 2	1 (Ref.)	1.04 (0.66, 1.64)	1.16 (0.75, 1.80)	1.11 (0.73, 1.71)	0.560
	Model 3	1 (Ref.)	1.05 (0.68, 1.69)	1.15 (0.74, 1.78)	1.04 (0.65, 1.62)	0.741
	Cases/N	24/2372	47/2441	57/2380	97/2322	
Women	Model 1	1 (Ref.)	1.91 (1.21, 3.29)	2.38 (1.48, 3.84)	4.19 (2.68, 6.55)	<0.001
	Model 2	1 (Ref.)	1.45 (0.89, 2.37)	1.25 (0.78, 2.03)	1.90 (1.21, 2.99)	0.006
	Model 3	1 (Ref.)	1.43 (0.87, 2.33)	1.30 (0.80, 2.09)	1.92 (1.22, 3.01)	0.004

Model 1: unadjusted model; Model 2: adjusted for age, sex and BMI; Model 3: further adjusted for HDL-C, TC, TG, LDL-C, eGFR, hypertension, smoking status, use of statins and family history of stroke.



Appendix S1. Flow chart



Appendix S2. Hazard ratios (95% CI) for incident stroke by menopausal status in women

			Model 1	Model 2	Model 3
Premenopausal	Q1	Cases/N		1/906	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	Q2	Cases/N		5/896	
		HR (95%CI)	5.07 (0.59, 43.37)	2.97 (0.34, 25.86)	2.54 (0.29, 22.48)
	Q3	Cases/N		7/883	
		HR (95%CI)	7.19 (0.89, 58.44)	3.88 (0.47, 31.97)	3.86 (0.47, 31.78)
	Q4	Cases/N		8/884	
HR (95%CI)		8.18 (0.29, 22.48)	1.90 (0.22, 16.15)	1.80 (0.21, 15.30)	
P trend			0.013	0.850	0.916
Postmenopausal or oophorectomy	Q1	Cases/N		35/1489	
		HR (95%CI)	1 (Ref.)	1 (Ref.)	1 (Ref.)
	Q2	Cases/N		42/1513	
		HR (95%CI)	1.18 (0.76, 1.85)	1.05 (0.67, 1.64)	1.06 (0.62, 1.79)
	Q3	Cases/N		49/1473	
		HR (95%CI)	1.42 (0.92, 2.19)	1.07 (0.69, 1.66)	1.14 (0.70, 1.87)
	Q4	Cases/N		78/1471	
HR (95%CI)		2.28 (1.53, 3.40)	1.66 (1.11, 2.28)	1.68 (1.06, 2.68)	
P trend			<0.001	0.006	0.006

Model 1: unadjusted model; Model 2: Adjusted for age and BMI; Model 3: further adjusted for HDL-C, TC, TG, LDL-C, eGFR, hypertension, use of statins and family history of stroke.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2	Design
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Results
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6	
Objectives	3	State specific objectives, including any prespecified hypotheses	5	
Methods				
Study design	4	Present key elements of study design early in the paper	7	Study population
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7	Study population
		(b) For matched studies, give matching criteria and number of exposed and unexposed	7	Study population
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8	
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8	
Bias	9	Describe any efforts to address potential sources of bias	7	Study population
Study size	10	Explain how the study size was arrived at	7	Study population
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9	Statistical analysis
		(b) Describe any methods used to examine subgroups and interactions	8-9	Statistical analysis
		(c) Explain how missing data were addressed	8-9	Statistical analysis
		(d) If applicable, explain how loss to follow-up was addressed	8-9	Statistical analysis
		(e) Describe any sensitivity analyses	8-9	Statistical analysis

Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11	Characteristics of the study population
		(b) Give reasons for non-participation at each stage	11	Characteristics of the study population
		(c) Consider use of a flow diagram		supplemental appendix S1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11	tables
		(b) Indicate number of participants with missing data for each variable of interest	11	Characteristics of the study population
		(c) Summarise follow-up time (eg, average and total amount)	11	tables
Outcome data	15*	Report numbers of outcome events or summary measures over time	11	tables
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-12	tables and figures
		(b) Report category boundaries when continuous variables were categorized	11-12	tables and figures
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11-12	tables and figures
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12	Meta-analysis
Discussion				
Key results	18	Summarise key results with reference to study objectives	13	Principal findings
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-16	Strengths and Limitations
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15	Possible mechanisms
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14	
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if	18	Funding

applicable, for the original study on which the
present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

For peer review only